AD 32,
AD-32,
N-trifluoroacetyladriamycin 14-valerate,
NSC-246131,
valrubicin,
Valstar,
Valtaxin,
Valrubicin,
56124-62-0,
AD-32,
Valstar,
UNII-2C6NUM6878,
Antibiotic AD 32,
Valtaxin,
N-Trifluoroacetyladriamycin-14-valerate,
2C6NUM6878,
NSC-246131,
AD 32,
Valstar Preservative Free,
N-Trifluoroacetyldoxorubicin 14-valerate,
HSDB 7288,
C34H36F3NO13,
Trifluoroacetyladriamycin-14-valerate,
NSC 246131,
Valrubicina,
Valrubicine,
Valrubicinum,
Valrubicin [USAN:USP:INN],
NSC246131,
NCGC00164738-01,
(2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester,
Adriamycin, trifluoroacetyl-, 14-valerate,
Valrubicin (AD-32),
AC1L9RHG,
DSSTox_CID_26497,
DSSTox_RID_81666,
DSSTox_GSID_46497,
SCHEMBL12824,
AD32,
CHEMBL1096885,
DTXSID9046497,
AOB2165,
EX-A493,
CHEBI:135876,
(2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate,
(8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate,
Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester,
Tox21_112257,
ZINC49783788,
CS-2929,
DB00385,
HY-13772,
CAS-56124-62-0,
FT-0655298,
D02697,
Z-3187,
124V620,
Q-101408,
(2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-.alpha.-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl ester,
(8S, 10S)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-[[2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione 8(2)-valerate,
[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[(2R,4S,5S,6S)-5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate,
[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[(2R,4S,5S,6S)-5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]tetrahydropyran-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate,
2-oxo-2-((2S,4S)-2,5,12-trihydroxy-4-((2R,4S,5S,6S)-5-hydroxy-6-methyl-4-(2,2,2-trifluoroacetamido)tetrahydro-2H-pyran-2-yloxy)-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)ethyl pentanoate,
2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-({2,3,6-trideoxy-3-[(trifluoroacetyl)amino]hexopyranosyl}oxy)-1,2,3,4,6,11-hexahydrotetracen-2-yl]ethyl pentanoate,
Valstar (TN),
Valrubicin [USAN],
Valrubicin (USP/INN),
N-Trifluoroacetyladriamycin 14-valerate,
CID454216,
ACN-036870,
C34-H36-F3-N-O13,
B3447,
C016163,
Pentanoic acid, 2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(trifluoroacetyl)amino]-.alpha.-L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethyl ester, (2S-cis)-,